ArticleCell2024
A potent pan-sarbecovirus neutralizing antibody resilient to epitope diversification.
Abstract read
In one paragraph
Article in Cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- An IgG-like fusion protein comprising an anti-spike S2 antibody and ACE2 exhibits potent and broad neutralization against SARS-CoV-2 and variants of concern.Antibody therapeutics · 2026Article
- Article
- Emergence of neutralizing RBD antibodies following Omicron infection with limited activity against ancestral SARS-CoV-2.iScience · 2026Article
- Receptor-mimicking antibodies retain neutralization of recent SARS-CoV-2 variants.Biosafety and health · 2026Article
- Localized Rigidification and Allosteric Modulation Mechanisms of SARS-CoV-2 Spike Neutralization by Class 3 and Class 4 Antibodies at Atomic Resolution: An Integrated Computational Study of Binding, Dynamics, and Allostery.bioRxiv : the preprint server for biology · 2026Article
- It started off as a Cys, how did it end up like this? Identifying the extent of unmodelled oxidatively modified cysteines within the Protein Data Bank.Acta crystallographica. Section D, Structural biology · 2026Article
- Broad Neutralizing Antibodies Against SARS-CoV-2: Current Progress and Engineering Strategies.Viruses · 2026Review
- Atomic layer deposition for core-shell microparticle vaccines enabling programmable antigen delivery to lymph nodes enhance humoral immune responses.bioRxiv : the preprint server for biology · 2026Article
- Deep mutational scanning of recent SARS-CoV-2 variants highlights changing amino acid preferences within epistatic hotspot residues.PLoS pathogens · 2026Article
- Computational design of an ultrapotent deltacoronavirus miniprotein inhibitor.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- TMPRSS2-mediated coronavirus spike activation and inhibition.Nature structural & molecular biology · 2026Article
- Mechanisms of Binding and Immune Escape Resistance for Broadly Neutralizing Antibodies Targeting Distinct Conserved SARS-CoV-2 Spike Epitopes: A Hierarchical Approach Integrating Mutational Profiling and Energy Landscape Analysis.International journal of molecular sciences · 2026Article
- SARS-CoV-2 vaccination and infection elicit cross-neutralizing responses against clade 3 and 4 sarbecoviruses.Nature communications · 2026Article
- Observation of redistribution for local conformational dynamics in cross-reactive antibody design.Journal of biochemistry · 2026Article
- Article
- Frustration Landscapes of Broadly Neutralizing SARS-CoV-2 Spike Antibodies Targeting Conserved Epitopes Reveal Energetic Logic of Escape-Proof and Escape-Prone Mechanisms.bioRxiv : the preprint server for biology · 2026Article
- An integrated computational antigen discovery pipeline with hierarchical filtering for emerging viral variants.NAR molecular medicine · 2026Article
- Exploring the diverse binding ability of SARS-CoV-2 variant RBDs to different antibody classes: a computational study.RSC advances · 2026Article
- Discovery of Anti-SARS-CoV-2 XBB.1.5 and JN.1 Variant-Specific Monoclonal Single-Domain Antibodies from a Synthetic Library.Antibodies (Basel, Switzerland) · 2026Article
- Optimized ACE2-Fc fusion proteins with picomolar neutralization activity against highly evolved SARS-CoV-2 variants.Protein science : a publication of the Protein Society · 2026Article
Corrections and comments
- Commented on by
Authors and funding
53 authors.
Laura E RosenVir Biotechnology, San Francisco, CA 94158, USA.
M Alejandra TortoriciDepartment of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Anna De MarcoHumabs BioMed SA, a Subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Dora PintoHumabs BioMed SA, a Subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
William B ForemanDepartment of Biochemistry, University of Utah School of Medicine, Salt Lake City, UT 84112, USA.
Ashley L TaylorDepartment of Biochemistry, University of Utah School of Medicine, Salt Lake City, UT 84112, USA.
Young-Jun ParkDepartment of Biochemistry, University of Washington, Seattle, WA 98195, USA; Howard Hughes Medical Institute, University of Washington, Seattle, WA 98195, USA.
Dana BohanVir Biotechnology, San Francisco, CA 94158, USA.
Tyson RietzVir Biotechnology, San Francisco, CA 94158, USA.
John M ErricoVir Biotechnology, San Francisco, CA 94158, USA.
Kevin HauserVir Biotechnology, San Francisco, CA 94158, USA.
Ha V DangVir Biotechnology, San Francisco, CA 94158, USA.
Justin W ChartronProtaBody, Pasadena, CA 91105, USA.
Martina GiurdanellaHumabs BioMed SA, a Subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Giuseppe CusumanoHumabs BioMed SA, a Subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Christian SalibaHumabs BioMed SA, a Subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Fabrizia ZattaHumabs BioMed SA, a Subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Kaitlin R SprouseDepartment of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Amin AddetiaDepartment of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Samantha K ZepedaDepartment of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Jack BrownDepartment of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Jimin LeeDepartment of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Exequiel DellotaVir Biotechnology, San Francisco, CA 94158, USA.
Anushka RajeshVir Biotechnology, San Francisco, CA 94158, USA.
Julia NoackVir Biotechnology, San Francisco, CA 94158, USA.
Qiqing TaoVir Biotechnology, San Francisco, CA 94158, USA.
Yvonne DaCostaVir Biotechnology, San Francisco, CA 94158, USA.
Brian TsuVir Biotechnology, San Francisco, CA 94158, USA.
Rima AcostaVir Biotechnology, San Francisco, CA 94158, USA.
Sambhavi SubramanianVir Biotechnology, San Francisco, CA 94158, USA.
Guilherme Dias de MeloInstitut Pasteur, Université Paris Cité, Lyssavirus Epidemiology and Neuropathology Unit, F-75015 Paris, France.
Lauriane KergoatInstitut Pasteur, Université Paris Cité, Lyssavirus Epidemiology and Neuropathology Unit, F-75015 Paris, France.
Ivy ZhangComputational and Systems Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Tri-Institutional PhD Program in Computational Biology and Medicine, Weill Cornell Graduate School of Medical Sciences, New York, NY 10065, USA.
Zhuoming LiuDepartment of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Barbara GuarinoHumabs BioMed SA, a Subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Michael A SchmidHumabs BioMed SA, a Subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Gretja SchnellVir Biotechnology, San Francisco, CA 94158, USA.
Jessica L MillerVir Biotechnology, San Francisco, CA 94158, USA.
Florian A LemppVir Biotechnology, San Francisco, CA 94158, USA; Humabs BioMed SA, a Subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Nadine CzudnochowskiVir Biotechnology, San Francisco, CA 94158, USA.
Elisabetta CameroniHumabs BioMed SA, a Subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Sean P J WhelanDepartment of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Hervé BourhyInstitut Pasteur, Université Paris Cité, Lyssavirus Epidemiology and Neuropathology Unit, F-75015 Paris, France.
Lisa A PurcellVir Biotechnology, San Francisco, CA 94158, USA.
Fabio BenigniHumabs BioMed SA, a Subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Julia di IulioVir Biotechnology, San Francisco, CA 94158, USA.
Matteo Samuele PizzutoHumabs BioMed SA, a Subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Antonio LanzavecchiaHumabs BioMed SA, a Subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Amalio TelentiVir Biotechnology, San Francisco, CA 94158, USA.
Gyorgy SnellVir Biotechnology, San Francisco, CA 94158, USA.
Davide CortiHumabs BioMed SA, a Subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Electronic address: dcorti@vir.bio.
David VeeslerDepartment of Biochemistry, University of Washington, Seattle, WA 98195, USA; Howard Hughes Medical Institute, University of Washington, Seattle, WA 98195, USA. Electronic address: dveesler@uw.edu.
Tyler N StarrDepartment of Biochemistry, University of Utah School of Medicine, Salt Lake City, UT 84112, USA. Electronic address: tyler.starr@biochem.utah.edu.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MUTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6MA Synchrotron Radiation Structural Biology ResourcesP30GM133894 · NIGMS · STANFORD UNIVERSITY · PI Aina E. Cohen, KEITH O HODGSON · 2020 to 2026
$43.3MUser Training and OutreachP30GM124169 · NIGMS · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI Gregory L Hura · 2017 to 2026
$28.6MCenters for Research on Structural Biology of Infectious Diseases: Universal Influenza Vaccine Research75N93022C00036 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI STAKER, BART · 2022 to 2025
$21.7MStructure-based design of broadly protective coronavirus vaccinesP01AI167966 · NIAID · UNIVERSITY OF WASHINGTON · PI BALI PULENDRAN · 2022 to 2026
$15.3MUnraveling the bat humoral immune response against zoonotic viruses to guide the design of next-generation therapeuticsDP1AI158186 · NIAID · UNIVERSITY OF WASHINGTON · PI VEESLER, DAVID · 2020 to 2024
$5.4MUnderstanding spillover potential of European and African bat sarbecovirusesF31AI174573 · NIAID · UNIVERSITY OF WASHINGTON · PI ZEPEDA, SAMANTHA KATHLEEN · 2023 to 2024
$88kHoward Hughes Medical InstituteNCI NIH HHS P30 CA008748NCI NIH HHS P30 CA042014NIAID NIH HHS 75N93022C00036NIAID NIH HHS DP1 AI158186NIAID NIH HHS F31 AI174573NIAID NIH HHS P01 AI167966NIGMS NIH HHS P30 GM124169NIGMS NIH HHS P30 GM133894
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) evolution has resulted in viral escape from clinically authorized monoclonal antibodies (mAbs), creating a need for mAbs that are resilient to epitope diversification. Broadly neutralizing coronavirus mAbs that are sufficiently potent for clinical development and retain activity despite viral evolution remain elusive. We identified a human mAb, designated VIR-7229, which targets the viral receptor-binding motif (RBM) with unprecedented cross-reactivity to all sarbecovirus clades, including non-ACE2-utilizing bat sarbecoviruses, while potently neutralizing SARS-CoV-2 variants since 2019, including the recent EG.5, BA.2.86, and JN.1. VIR-7229 tolerates extraordinary epitope variability, partly attributed to its high binding affinity, receptor molecular mimicry, and interactions with RBM backbone atoms. Consequently, VIR-7229 features a high barrier for selection of escape mutants, which are rare and associated with reduced viral fitness, underscoring its potential to be resilient to future viral evolution. VIR-7229 is a strong candidate to become a next-generation medicine.
Indexed as
Antibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralEpitopesSARS-CoV-2Angiotensin-Converting Enzyme 2AnimalsChiropteraCOVID-19Cross ReactionsHumansSpike Glycoprotein, CoronavirusAngiotensin-Converting Enzyme 2Antibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralEpitopesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2broadly neutralizing antibodymonoclonal antibodysarbecovirusSARS-CoV-2viral antibody escape
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.